Blog

The United States continues to lead the global genomics life science analytics market, driven by technological advancements, increasing demand for personalized medicine, and substantial investments in research and development. This article delves into the latest trends, growth projections, and opportunities shaping the U.S. market in 2025 and 2026.

Market Overview

Market Size and Growth

In 2024, the U.S. genomics market was valued at USD 14.03 billion. It is projected to grow at a CAGR of 16.81% from 2025 to 2035, reaching USD 77.54 billion by 2035.

The U.S. life science analytics market is also experiencing significant growth, with projections indicating a market size of USD 28.66 billion by 2034.

Key Market Segments

By Product Type

• Software Solutions: In 2024, software solutions dominated the market with nearly 65% share, driven by the adoption of big data analytics and cloud-based solutions.

By Application

• Drug Discovery & Development: This segment led the market with approximately 40% share in 2024, fueled by the need for rapid and cost-effective drug development processes.

• Clinical Diagnostics & Personalized Medicine: Expected to grow at the fastest CAGR during 2025–2034, driven by advancements in technologies like NGS and CRISPR.

By Technology

• Next-Generation Sequencing (NGS) Analytics: Held the largest revenue share of approximately 70% in 2024, due to the increasing volume and complexity of biological data.

By Deployment Mode

• On-Premises: Led the market with approximately 60% revenue share in 2024, though cloud-based deployment is expected to grow rapidly in the coming years.

By End Use

• Pharmaceutical & Biotechnology Companies: Accounted for nearly 45% of the market in 2024, reflecting the sector’s reliance on genomics analytics for drug development and research.

Market Drivers

Technological Advancements

The integration of AI and machine learning in genomics analytics is enhancing drug discovery processes, enabling precision medicine, and accelerating disease risk estimation.

Personalized Medicine

The growing demand for treatments tailored to individual genetic profiles is a significant driver, with life science analytics playing a crucial role in integrating and analyzing vast datasets to support precision medicine initiatives.

Government and Private Investments

Increased funding and investments in life sciences research and development, particularly in genomics and personalized medicine, are propelling market growth.

Market Challenges

Data Privacy and Security

Managing large datasets containing sensitive patient information raises concerns about data privacy and security, posing challenges for organizations in the genomics analytics space.

High Costs

The expenses associated with advanced analytics software, infrastructure, and skilled personnel can be prohibitive for some organizations, potentially hindering market growth.

Future Outlook (2025–2026)

The U.S. genomics life science analytics market is poised for continued growth in 2025 and 2026, driven by technological innovations, increasing adoption of personalized medicine, and supportive government policies. The integration of AI and machine learning is expected to further enhance analytics capabilities, leading to more efficient drug discovery and improved patient outcomes.

Source : Towards Healthcare. “Genomics Life Science Analytics Market.” towardshealthcare.com

China is rapidly emerging as a pivotal force in the Asia-Pacific women’s digital health market. With significant investments in technology, a burgeoning health-tech startup ecosystem, and proactive government support, the nation is reshaping the landscape of women’s healthcare across the region.

Market Overview: Rapid Growth Trajectory

The women’s digital health market in China is experiencing robust growth. In 2023, the market was valued at approximately USD 131.1 million and is projected to reach USD 564.5 million by 2030, registering a compound annual growth rate (CAGR) of 23.2% from 2024 to 2030.

This growth is fueled by increasing awareness of women’s health issues, the proliferation of digital health solutions, and a supportive regulatory environment.

Key Market Segments and Trends

1. Mobile Applications

Mobile health applications dominate China’s women’s digital health market, accounting for 65.75% of the revenue share in 2023. These apps offer services ranging from menstrual tracking to fertility monitoring, catering to the evolving needs of women.

2. Wearable Devices

Wearable health devices are the fastest-growing segment, anticipated to witness significant adoption due to their ability to provide real-time health monitoring and personalized insights.

3. Diagnostic Tools

Diagnostic tools are projected to reach USD 240.5 million by 2032, growing at a CAGR of 27.40% from 2023 to 2032. These tools enhance early detection and management of women’s health conditions.

 China’s Role in the Asia-Pacific Market

In the broader Asia-Pacific context, the women’s digital health market is projected to grow from USD 724.17 million in 2024 to USD 5,691.42 million by 2034, at a CAGR of 22.74%. China’s significant investments and advancements position it as a key contributor to this regional growth.

Government Initiatives and Policy Support

The Chinese government has implemented several initiatives to promote digital health, including:

• “Healthy China 2030” Plan: Aims to improve healthcare services and promote health education.

• Telemedicine Expansion: Policies encouraging the development and adoption of telehealth services, especially in rural areas.

These initiatives create a conducive environment for the growth of women’s digital health solutions.

 Innovations and Future Outlook

China’s focus on integrating artificial intelligence (AI) and big data analytics into healthcare is set to revolutionize women’s health services. Innovations in personalized medicine, predictive analytics, and remote monitoring are expected to enhance the quality and accessibility of care.

Source :

1. Towards Healthcare. “Asia-Pacific Women’s Digital Health Market Sizing.” Linktowardshealthcare.com

The United Kingdom is rapidly emerging as a global leader in artificial intelligence (AI) and machine learning (ML) applications within the pharmaceutical sector. With substantial investments, groundbreaking research, and strategic collaborations, the UK is poised to revolutionize drug discovery and development processes. This article delves into the latest statistical data and developments from 2025 and 2026, highlighting the UK’s pivotal role in this transformative landscape.

---

Market Growth and Projections

• Market Valuation: As of 2025, the UK’s AI in drug discovery market is valued at approximately USD 1.8 billion, with projections indicating a growth to USD 14.0 billion by 2033, reflecting a Compound Annual Growth Rate (CAGR) of 23.17% during the forecast period.

• Global Context: Globally, the AI in drug discovery market reached USD 1.5 billion in 2023 and is expected to expand at a CAGR of 29.7% from 2024 to 2030, underscoring the UK’s significant contribution to this global trend.

---

Government Initiatives and Funding

• OpenBind Consortium: In June 2025, the UK government launched the OpenBind consortium, aiming to position the UK at the forefront of AI-driven drug discovery. This initiative is projected to slash drug development costs by up to £100 billion, enhancing the efficiency and affordability of new therapeutics.

• Research Funding: The government has pledged £82.6 million in research funding to support AI companies focused on accelerating drug development. This includes £37.9 million allocated to three British research projects under the Research Ventures Catalyst (RVC) programme, complemented by £44.7 million in co-investment from various sources.

---

Technological Advancements and Collaborations

• AlphaFold Breakthrough: In 2025, Google DeepMind’s co-founder, Sir Demis Hassabis, and director Dr. John Jumper received the Nobel Prize for their work on AlphaFold, an AI system capable of predicting protein structures with remarkable accuracy. This advancement has significantly accelerated the identification of potential drug targets.

• Industry Partnerships: UK-based biotech companies like Antiverse, Exscientia, and HealX are leveraging AI to design novel therapeutics. For instance, Antiverse announced a partnership with Japan’s Nxera to develop AI-designed antibodies, exemplifying the UK’s collaborative efforts in this domain.

---

Academic and Research Contributions

• Oxford’s OpenBind Project: The University of Oxford’s Department of Statistics is leading the OpenBind project, backed by the UK’s Sovereign AI Unit. This initiative aims to train next-generation AI models for drug discovery and establish new standards for open scientific data sharing, reinforcing the UK’s commitment to collaborative research.

---

Challenges and Considerations

While the UK is making significant strides, challenges persist:

• Data Quality and Availability: The effectiveness of AI models depends on high-quality, comprehensive datasets. Ensuring data standardization and integration remains a priority.

• Ethical and Regulatory Frameworks: Balancing innovation with ethical considerations, such as data privacy and algorithm transparency, is crucial for sustained progress.

---

Future Outlook

Looking ahead to 2026 and beyond, the UK’s focus on AI-driven drug discovery is expected to yield substantial benefits:

• Accelerated Drug Development: AI is anticipated to reduce the average time for drug development from 10–15 years to a significantly shorter timeframe, enhancing the responsiveness to emerging health challenges.

• Cost Efficiency: The integration of AI is projected to lower the average cost of bringing a new drug to market, making treatments more accessible.

• Global Leadership: With ongoing investments and collaborations, the UK is well-positioned to lead global efforts in AI-driven pharmaceutical innovation.

---

Conclusion

The United Kingdom’s strategic investments, robust research infrastructure, and collaborative initiatives are propelling it to the forefront of AI-driven drug discovery. As the nation continues to harness the power of AI and ML, it stands to revolutionize the pharmaceutical industry, offering faster, more cost-effective, and precise therapeutic solutions to meet global health needs.

---

Sources

• UK to become world leader in drug discovery as Technology Secretary heads for London Tech Week

• UK awards £82.6m to AI drug discovery companies

• Even a sceptic can see AI will transform the discovery of drugs

• New consortium to make UK a world leader in AI drug discovery

• Oxford Statistics at the forefront of AI-driven drug discovery

• Towards Healthcare

The global CAR-T cell therapy market for multiple myeloma is witnessing rapid growth, with the United States emerging as the clear leader. In 2025 and 2026, the U.S. is expected to dominate this market due to advanced healthcare infrastructure, regulatory approvals, and significant investments in innovative cancer treatments.

---

Market Size and Growth Projections

In 2024, the CAR-T cell therapy market for multiple myeloma was valued at USD 3.4 billion. By 2033, it is projected to reach USD 12.6 billion, growing at a CAGR of 15.8% from 2026 to 2033.

The broader global CAR-T cell therapy market is also set for expansion, with estimates showing growth from USD 8.46 billion in 2025 to USD 88.51 billion by 2034, at a CAGR of 29.8%.

---

Key Market Drivers

1. United States’ Advanced Healthcare Ecosystem

The U.S. boasts an advanced healthcare infrastructure and robust clinical research network, positioning it as the top country for CAR-T cell therapy development and adoption.

2. Regulatory Support

In 2025, the FDA removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for approved CAR-T therapies. This change has streamlined access for healthcare providers and patients.

3. Rising Multiple Myeloma Cases

Over 32,000 new cases of multiple myeloma are diagnosed annually in the United States alone, driving demand for cutting-edge treatments.

4. Technological Innovation

Advancements in CAR-T cell engineering are enhancing efficacy and safety, attracting investment from both pharmaceutical giants and biotech startups.

---

Leading Therapies and Clinical Developments

Approved Therapies in the U.S.

Abecma (idecabtagene vicleucel): Bristol Myers Squibb’s BCMA-directed therapy is approved for relapsed/refractory multiple myeloma.

Carvykti (ciltacabtagene autoleucel): Johnson & Johnson and Legend Biotech’s CAR-T therapy has demonstrated a 45% reduction in mortality risk over three years.

Emerging U.S. Therapies

Anito-cel: Gilead Sciences and Arcellx’s candidate achieved a 97% response rate in clinical trials, with 62% of patients showing complete responses.

---

Regional Market Insights

United States – The Global Leader

The U.S. leads the CAR-T cell therapy market thanks to FDA approvals, research investments, and partnerships between major pharmaceutical companies and biotech innovators.

Asia-Pacific – The Fastest Growing Region

Countries like China and Japan are catching up with increasing healthcare investments and clinical trials.

---

Future Outlook

With robust clinical pipelines and regulatory support, the U.S. CAR-T cell therapy market for multiple myeloma will remain dominant through 2025 and 2026. Other regions are expected to follow suit as access to these therapies expands globally.

---

Sources

• CAR T-Cell Therapies Market Size Skyrockets 29.8% CAGR by 2034 – Towards Healthcare

• CAR T-Cell Therapy for Multiple Myeloma Market | 2025-2033 – Market Growth Reports

• CAR T-Cell Therapy for Multiple Myeloma Market’s Strategic Roadmap – Data Insights Market

• Legend Biotech: J&J-Tied Cancer Drug Cuts Risk Of Death By 45% – Investors.com

• Arcellx and Legend Bio Trade Jabs in Multiple Myeloma – Investors.com

The global cryopreservation and platelet storage technologies market is witnessing robust growth, driven by advancements in regenerative medicine, biobanking expansion, and rising demand for fertility preservation. This article provides detailed insights into market trends, statistical data for 2025 and 2026, and highlights how the United States remains the leading country in this sector.

Market Overview

The global cell cryopreservation market was valued at USD 11.48 billion in 2024 and is projected to grow to USD 13.89 billion in 2025, with a CAGR of 21.05% from 2024 to 2034. This surge is driven by the widespread use of cryopreservation in stem cell therapy, organ transplantation, and fertility services.

Key Market Drivers

1. Regenerative Medicine Advancements: The rise in biologics and targeted therapies has increased reliance on cryopreserved cells for research and clinical trials.

2. Rising Infertility Rates: Global infertility rates are prompting higher demand for egg and sperm cryopreservation services.

3. Technological Innovations: Modern freezing protocols and automation ensure higher cell viability during storage.

4. Biobanking Expansion: Developed nations are increasingly investing in biobanking infrastructure, further boosting demand.

Regional Insights

• North America, led by the United States, dominates the global market with its strong healthcare infrastructure and investments in advanced cryopreservation technologies.

• Asia-Pacific is forecasted to grow rapidly, driven by supportive government policies and growing awareness of fertility preservation.

Leading Countries in the Market

1. United States: As the market leader, the U.S. benefits from high R&D investments, major players like Thermo Fisher Scientific and BioLife Solutions, and advanced medical facilities.

2. Germany: Leads Europe with a strong biotech sector and favorable government initiatives.

3. Japan: Innovations in aging population healthcare solutions bolster its market position.

4. China: Emerging as a significant player due to increasing biobanking and healthcare investments.

Platelet Storage Technologies

Traditionally, platelets were stored at room temperature for 5–7 days. With modern cryopreservation, they can now be stored at ultra-low temperatures, extending their usability for transfusions and reducing wastage.

Conclusion

The U.S. continues to lead the global cryopreservation and platelet storage technologies market. With growing applications in regenerative medicine and biobanking, and technological advances supporting long-term storage, the market is poised for remarkable growth through 2026.

---

Source

• Towards Healthcare. (2025). Cell Cryopreservation Market Size, Companies, Trends and Developments. Read More

Artificial Intelligence (AI) is revolutionizing the life sciences sector, driving innovations in drug discovery, clinical trials, diagnostics, and personalized medicine. Between 2025 and 2026, the global AI in life sciences market is experiencing significant growth, fueled by technological advancements, increased investments, and the pressing need for efficient healthcare solutions.

---

📊 Market Overview: 2025–2026

• Market Size: The global AI in life sciences market is projected to grow from USD 2.71 billion in 2025 to USD 14.20 billion by 2034, reflecting a CAGR of 20.21% over the forecast period.

• Regional Insights:

  • North America dominated the market in 2024, accounting for approximately 49% of the global share.

  • Asia-Pacific is anticipated to be the fastest-growing region from 2025 to 2034, driven by increasing investments in healthcare technology and AI-driven research initiatives.

• Key Growth Drivers:

  • Rising demand for personalized medicine and targeted therapies.

  • Advancements in machine learning algorithms and big data analytics.

  • Increasing collaborations between tech companies and pharmaceutical firms.

---

🧪 Applications of AI in Life Sciences

1. Drug Discovery & Development:

   • AI accelerates the identification of potential drug candidates, reducing the time and cost associated with traditional methods.

   • Approximately 70% of drug companies utilize AI for target identification and validation.

2. Clinical Trials:

   • AI enhances patient recruitment, monitoring, and data analysis, leading to more efficient trials.

   • AI tools are predicted to boost the success rate of clinical trials by approximately 20% in the next five years.

3. Diagnostics:

   • AI-powered diagnostics are expected to reduce diagnostic errors by up to 50%, improving patient outcomes.

4. Personalized Medicine:

   • Machine learning models have achieved a 40% increase in predictive accuracy for disease progression in oncology studies.

---

💼 Investment and Strategic Developments

• Corporate Investments:

  • Major tech companies like Amazon, Nvidia, Microsoft, and Google are intensifying their investments in AI-driven medical solutions.

• Startups and Collaborations:

  • UK-based Antiverse partnered with Japan’s Nxera to utilize AI in antibody design, showcasing the global collaboration trend in AI-driven drug development.

---

🌐 Global Leaders in AI for Life Sciences

• United States: Leading in market share due to advanced healthcare infrastructure and significant R&D investments.

• China and India: Emerging as significant players with increasing investments in AI research and a growing biotech sector.

• Europe: Countries like the UK and Germany are investing in AI to enhance their pharmaceutical and biotech industries.

---

🔮 Future Outlook: 2026 and Beyond

The integration of AI in life sciences is expected to deepen, with advancements in areas like genomics, proteomics, and real-world evidence generation. As AI technologies mature, their application will expand, leading to more efficient healthcare systems and improved patient outcomes globally.

---

📚 Sources

• Towards Healthcare. AI In Life Sciences Market Skyrockets 20.21% CAGR by 2034.

• Towards Healthcare. AI In Life Sciences Key Players-Business, Deal & Patent Strategies.

• Towards Healthcare. AI in Life Science Market Companies and Strategic Solutions.

The contamination detection in pharmaceutical products market is experiencing remarkable growth in 2025. This surge is driven by strict government regulations, a booming healthcare production sector, and heightened awareness about product safety. Technologies such as chromatography, spectroscopy, and rapid microbiological methods play a critical role in identifying contaminants in drugs, biologics, and medical devices.

Why is This Market Growing?

The demand for contamination detection solutions is increasing as pharmaceutical companies focus on ensuring drug safety and quality. North America dominates the global market due to high demand for advanced-quality medicines and the presence of innovative detection technologies. Meanwhile, Asia Pacific is emerging as the fastest-growing region, with pharmaceutical giants investing heavily in R&D to enhance detection speed and sensitivity.

Market Highlights for 2025

• North America leads with a 45.2 percent market share in 2024.

• Asia Pacific is expected to grow at the fastest CAGR from 2025 to 2035.

• Chemical contamination accounted for the largest market share (36.5 percent) in 2024.

• Microbial contamination is forecasted as the fastest-growing segment between 2025 and 2035.

• Spectroscopy-based detection technologies dominated in 2024 with a 34.2 percent share.

Invest in Our Premium Strategic Solution:  https://www.towardshealthcare.com/download-databook/5800

Trends Shaping the Market in 2025

Government Initiatives Boosting Local Production

India’s PLI Scheme for Bulk Drugs helped it transition from a net importer to a net exporter of critical pharmaceutical ingredients by 2025. This achievement narrowed the gap between domestic production capacity and demand.

Rising Investments in Manufacturing Facilities

Chrysalis launched GMP-ready spaces in Massachusetts and North Carolina, indicating growing investments in contamination control facilities.

Transparency in Chemical Contaminants

The U.S. FDA introduced the Chemical Contaminants Transparency Tool, an online database listing potential chemical threats in food and drugs, reinforcing the importance of monitoring contaminants.

Role of AI in Contamination Detection

AI-driven technologies are revolutionizing contamination detection by enabling real-time monitoring. These systems identify defects early, allow quick interventions, and prevent defective products from reaching consumers. This integration ensures improved product quality, safety, and manufacturing efficiency.

Get All the Details in Our Solutions – Access Report Preview: https://www.towardshealthcare.com/download-sample/5800

Market Dynamics

Drivers

Rising Use of Biologics and Biosimilars
Biologics are sensitive to microbial and particulate contamination. The growing demand for these therapies amplifies the need for advanced detection systems.

Restraints

Compliance Challenges
Issues like lack of GMP knowledge and inconsistent enforcement of standards are barriers to the market’s progress.

Opportunities

Adoption of Portable Devices
Portable contamination detection devices are gaining popularity for on-site testing. However, improving sample pretreatment methods remains a growth opportunity.

Segmental Insights

Why Chemical Contamination Leads

Chemical contamination dominated in 2024 because of the diverse chemicals used in pharmaceutical production that may accidentally interact with drug products.

Why Microbial Contamination is Growing Fast

The presence of microorganisms like bacteria, fungi, and viruses in pharma products pushes companies to invest in stringent microbiological testing and sanitation practices.

Why Spectroscopy Technology is Preferred

Spectroscopy offers a cost-effective, non-invasive method with fast results, making it a dominant technology in 2024.

Why Instruments Are in Demand

Instruments for contamination detection ensure high-quality control during manufacturing, helping prevent unsafe products from entering the market.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com

Regional Overview

North America

With 45.2 percent market share, North America leads thanks to advanced pharmaceutical production technologies and high demand for precision contamination detection systems.

Asia Pacific

The region is growing fastest due to increasing pharmaceutical manufacturing and biotechnology investments in countries like China and India.

Europe

Strong regulatory frameworks and growing investments in R&D drive Europe’s market growth. Germany, in particular, stands out for its innovation and rising pharmaceutical sales.

Recent Developments in 2025

• May 2025: Recipharm and ProductLife Group collaborate to accelerate clinical trials and market approvals.

• January 2025: bioMérieux acquired SpinChip Diagnostics, enhancing near-patient testing capabilities.

• May 2024: Merck launched M-Trace software for digitized sterility testing, reducing human error risks.

Frequently Asked Questions

What is driving the growth of contamination detection in pharmaceutical products in 2025?

The market is growing due to strict government regulations, rising demand for biologics, and technological advancements in detection methods like AI and portable devices.

Which region holds the largest market share in 2025?

North America dominates the market with a 45.2 percent share, owing to advanced pharmaceutical manufacturing technologies and growing biologics demand.

Why is the Asia Pacific region the fastest-growing?

Asia Pacific’s rapid growth is fueled by significant investments from global pharmaceutical companies in R&D and manufacturing capabilities.

Which contamination type leads the market?

Chemical contamination leads with a 36.5 percent share in 2024, due to frequent exposure of pharmaceutical products to chemical substances during manufacturing.

What role does AI play in this market?

AI enhances contamination detection by enabling real-time monitoring, quicker interventions, and improved product safety and quality.

To access the full market report : https://www.towardshealthcare.com/price/5800

The demand for CDMO (Contract Development and Manufacturing Organization) services in the pharmaceutical and biotechnology industries is rising sharply. As innovative treatments for complex diseases increase, companies are partnering with CDMOs to speed up development and commercialization. Additionally, artificial intelligence (AI) is transforming workflows, improving efficiency, and supporting global market growth.

North America Leads, Asia Pacific Emerges as a Growth Hotspot

In 2024, North America dominated the global CDMO services market, holding a 44.1% share. This leadership is driven by strong healthcare infrastructure, ongoing R&D investments, and a high rate of outsourcing by pharma and biotech companies.

Looking forward, Asia Pacific is set to be the fastest-growing region from 2025 to 2030. Countries like China and India are witnessing rising investments, clinical trials, and government support for CDMO services, positioning the region as a global manufacturing hub.

Invest in Our Premium Strategic Solution:  https://www.towardshealthcare.com/download-databook/5801

Service Type Trends: API Manufacturing Leads the Way

The API manufacturing segment emerged as the largest in 2024, holding a 41.3% market share. APIs (Active Pharmaceutical Ingredients) are vital for all medicines, and CDMOs help reduce production costs while ensuring compliance with regulations. This segment is also projected to register the fastest growth over the forecast period.

Small Molecules and Advanced Therapies: Shaping the Future

In 2024, small molecules dominated the market with a 58.2% share, supported by their widespread application in drug development. However, advanced therapies are anticipated to grow at the fastest pace in the coming years, driven by increasing demand for gene and cell therapies for chronic and rare diseases.

Commercial Phase Dominates, Clinical Segment on the Rise

By phase, the commercial segment led the market in 2024 with a 64.7% share. CDMOs play a critical role in large-scale production, quality assurance, and regulatory compliance during this phase. Meanwhile, the clinical segment is expected to grow rapidly as pharma and biotech companies seek to streamline clinical trials and accelerate product approvals.

Get All the Details in Our Solutions – Access Report Preview: https://www.towardshealthcare.com/download-sample/5801

Pharmaceutical Companies: The Major End Users

Pharmaceutical companies were the primary end users of CDMO services in 2024, accounting for a 69.5% market share. Their continuous drug development pipelines drive outsourcing needs. Biotech companies, however, are expected to show the highest growth, fueled by increasing biologics and advanced therapies production.

Oncology and Rare Diseases: Key Therapeutic Areas

The oncology segment was the largest therapeutic area in 2024, with a 33.8% share. Cancer treatments often require specialized CDMO support for production and clinical trials. The rare diseases segment is projected to grow fastest due to rising innovation in orphan drug development and supportive regulatory frameworks.

Role of AI in CDMO Services

AI is revolutionizing CDMO operations by improving quality, reducing time-to-market, and cutting costs. It helps optimize production conditions, predict potential issues, and enhance drug development processes. Predictive analytics and machine learning are also enabling smarter decision-making and operational efficiency.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com

Recent Collaborations and Developments

• June 2025: TAG1 Inc. partnered with PharmaLogic to improve accessibility to Pb-212 generators for radiopharmaceuticals.

• June 2025: OneSource Specialty Pharma Limited collaborated with Xbrane Biopharma AB for biosimilar manufacturing.

• June 2025: LOTTE BIOLOGICS signed a deal with Ottimo Pharma to support antibody therapeutics development.

• April 2025: PCI Pharma Services acquired Ajinomoto Althea to expand sterile fill-finish capabilities in North America.

• March 2025: Shilpa Medicare launched a hybrid CDMO to offer flexible pathways for pharma and biotech companies.

These collaborations highlight the growing reliance on CDMO services to support complex drug development and manufacturing needs globally.

FAQs

Q. What is driving the growth of CDMO services in 2025?

The growth is driven by increased outsourcing from pharma and biotech companies, the rise of innovative therapies, and the integration of AI for improved efficiency and cost savings.

Q. Why is API manufacturing the largest service segment?

API manufacturing dominates because of its critical role in drug production and the cost efficiencies CDMOs provide for API development and scaling.

Q. How is AI benefiting CDMO operations?

AI enhances quality control, reduces downtime, optimizes production conditions, and speeds up drug development, making CDMO operations more efficient and cost-effective.

Q. Which region is expected to grow fastest in the CDMO market?

Asia Pacific is projected to grow the fastest from 2025 to 2030, supported by rising investments, government initiatives, and the expanding pharma and biotech industries.

Q. Why are biotech companies increasing their use of CDMO services?

Biotech companies are leveraging CDMO expertise to develop biologics, gene therapies, and other advanced treatments that require specialized facilities and regulatory compliance.

To access the full market report : https://www.towardshealthcare.com/price/5801